Geneus Technologies was established in 2017 and is a high-tech company dedicated to the development and commercialization of fourth-generation (nanopore) gene sequencers and reagents. Its technology core is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and high-throughput sequencing of nucleic acids at the single molecule level through a highly integrated chip system. With the Nobel Prize participants and the world''s top nanopore sequencing experts as the core, Geneus Technologies has established a R & D team including senior experts in China and the United States in biochemistry, integrated circuits, materials, MEMS, organic synthesis, algorithms, etc., which has basically covered the professional fields required for the development of fourth-generation gene sequencers. The goal of Geneus Technologies is not only to break the monopoly of foreign countries in the field of sequencing equipment and reagents based on self-developed intellectual property rights, but also to use revolutionary technological breakthroughs to completely surpass the current popular second-generation sequencing technology in core indicators such as the quality (read length, sensitivity, coverage, etc.) and cost of sequencing data, subvert the existing sequencing field pattern, and achieve the goal of "a few hours, a few hundred yuan" to perform whole gene sequencing, and fully advance human whole genome sequencing into the clinical application field, so as to promote the development of precision medicine industry in both diagnosis and treatment, and thus become the leader in the global market related to up to 600 billion US dollars.

Since its establishment, Geneus Technologies has received a number of honors and special project funding, mainly including: 2018 Sichuan Province major science and technology special project; 2019 China Innovation and Entrepreneurship Competition National Finals Excellence Award, Sichuan Division Champion; 2022 is the "2022 In Vitro Diagnostics Qipu Seed Award TOP10". At present, Geneus Technologies has an elite team of 80 people, all of whom have undergraduate degrees or above. The core members have been selected as the Emei team in Sichuan Province. There are 2 experts in the Emei plan in Sichuan Province, 2 experts in Rong Bleaching, 1 talent in Shenzhen Peacock, 7 doctors, and 37 masters. It has precision equipment such as Agilent Liquid-Mass Combination, AKTA Protein Purification System, NGC Protein Purification System, Axon Patch Clamp Amplifier, Agilent Analytical HPLC, Bio-tek Enzyme Label Instrument, Gray Prepared HPLC, Beckman Centrifuge, Bio-Rad PCR Instrument, Nano-100 Microspectrophotometer, etc.

Geneus Technologies has a technology route with completely independent intellectual property rights, and has applied for some national invention patents and PCT priority. From the technical characteristics, the deep transformation of biochemical systems including nanopore proteins can more accurately capture effective sequencing signals; innovative chip design allows the integration of sequencing units on a single chip to reach tens of millions of orders of magnitude, much higher than the integration of congeneric products in the current market. Therefore, not only does it have an overwhelming advantage in data quality and cost compared with the mainstream second-generation sequencers in the market, but also compared with other fourth-generation sequencers, the target products of this project have outstanding advantages in accuracy, efficiency and cost reduction.

After more than 5 years of hard work by the team, Geneus Technologies has made a breakthrough in research and development. The company launched a 128-channel engineering prototype consistent with the final product architecture in 2020; on this basis, by further promoting R & D and industrialization work, we will launch a 512K-channel medium-throughput sample testing device in 2022; in the near future, we will also launch high-throughput and ultra-high-throughput sequencers with millions of pathways to achieve a comprehensive layout of scientific research and clinical applications, and thus become a leader in the global hundreds of billions of dollars of huge upstream and downstream markets, and finally realize the grand vision of "making gene sequencing a routine means of precision medicine and improving human health".